Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy-Reference-Cited by-同舟云学术

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

Published:2009-03-19 Issue:8 Volume:23 Page:1398-1405
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Mustjoki S,Ekblom M,Arstila T P,Dybedal I,Epling-Burnette P K,Guilhot F,Hjorth-Hansen H,Höglund M,Kovanen P,Laurinolli T,Liesveld J,Paquette R,Pinilla-Ibarz J,Rauhala A,Shah N,Simonsson B,Sinisalo M,Steegmann J L,Stenke L,Porkka K

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu200946.pdf

Reference20 articles.

1. Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet 2007; 370: 342–350.

2. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

3. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143–5150.

4. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207–3213.

5. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309.

Cited by 276 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials;Leukemia Research;2024-08

2. A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment;Clinics and Practice;2024-06-21

3. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML;Annals of Hematology;2024-04-18

4. Drug-induced chylothorax as a rare pleural complication in dasatinib therapy for chronic myeloid leukaemia;Journal of the Royal College of Physicians of Edinburgh;2024-03

5. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation;Leukemia;2023-11-02